About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Danicopan Early Access Program | Clinical Trials | Clareo Health

Back to clinical trial search

AVAILABLENCT05982938

Danicopan Early Access Program

This is an EAP, designed to provide early access to danicopan for participants with PNH experiencing clinically significant EVH who have failed, not tolerated, or are unable to receive other approved ...

Lead sponsor: Alexion Pharmaceuticals, Inc.•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Alexion Pharmaceuticals, Inc. (Sponsor)

CONTACT

1-855-752-2356 [email protected]

Sponsors

Lead Sponsor

Alexion Pharmaceuticals, Inc.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Male or female, aged 18 years and older
•Diagnosed with PNH with clinically significant EVH as defined by anemia (Hgb ≤ 9.5 g/dL) with absolute reticulocyte count ≥ 120 × 109/L.
•Currently receiving treatment with SOLIRIS® or ULTOMIRIS® for at least 6 months prior to initiation of danicopan treatment.
•Platelet count ≥ 30,000/µL without the need for platelet transfusions.
•Absolute neutrophil counts ≥ 500/µL.
•Vaccinated against N meningitidis.

Exclusion Criteria

•Participants who are nursing or pregnant (or women who are planning to become pregnant during treatment with danicopan).
•Laboratory abnormalities at screening, as follows:
•Alanine aminotransferase (ALT) \> 2 × upper limit of normal (ULN)
•Direct bilirubin \> 2 × ULN, with the exception of:
•* participants with increased bilirubin due to EVH in the opinion of the Treating Physician or
•* participants with documented Gilbert's syndrome
•Active bacterial or viral infection, a body temperature \> 38°C on 2 consecutive daily measures, evidence of other infection, or history of any febrile illness within 14 days prior to initiating danicopan treatment.

Related studies

RECRUITINGPhase 2

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

NCT03520647 · Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS), and more

RECRUITINGPhase 1/2

Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

NCT05876312 · Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

NCT06312644 · Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, and more

National Longitudinal Cohort of Hematological Diseases

NCT04645199 · Multiple Myeloma, Acute Myeloid Leukemia, and more

RECRUITINGPhase 3

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

NCT06449001 · Paroxysmal Nocturnal Hemoglobinuria, PNH, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 6, 2026Terms

Trial snapshot

StatusAVAILABLE

Phase—

Enrollment—

Start date—

Last updatedMar 6, 2026

Condition

Paroxysmal Nocturnal Hemoglobinuria PNH Extravascular Hemolysis

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 6, 2026Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions